Cell and gene therapies have emerged as promising treatments for previously untreatable diseases, and viral vectors are currently the preferred gene-delivery vehicle for most cell and gene therapies. For this reason, safe, robust, and cost-effective manufacturing processes are necessary to support the demands of the patient population. However, complexity around developing and scaling viral vector processes to commercial manufacturing scale, and the lack of standardized approaches, remain as challenges that can impact therapy development timelines and productivity. Selection of the appropriate production platform plays a key role in the successful implementation of a process that meets the commercialization timelines and manufacturing costs.
During this webinar, we will share two case studies that demonstrate successful scale-up for viral vectors, leveraging Pall’s platform, process expertise, and platform knowledge to help accelerate the development timelines.